These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 25500765)

  • 1. Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis.
    Hu J; Zheng X; Zhang W; Yang H
    Pituitary; 2015 Oct; 18(5):745-51. PubMed ID: 25500765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis.
    Xia MY; Lou XH; Lin SJ; Wu ZB
    Endocrine; 2018 Jan; 59(1):50-61. PubMed ID: 29043560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
    Dogansen SC; Selcukbiricik OS; Tanrikulu S; Yarman S
    Pituitary; 2016 Jun; 19(3):303-10. PubMed ID: 26830552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy.
    Colao A; Di Sarno A; Guerra E; Pivonello R; Cappabianca P; Caranci F; Elefante A; Cavallo LM; Briganti F; Cirillo S; Lombardi G
    Clin Endocrinol (Oxf); 2007 Sep; 67(3):426-33. PubMed ID: 17573902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
    Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
    N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis.
    Dekkers OM; Lagro J; Burman P; Jørgensen JO; Romijn JA; Pereira AM
    J Clin Endocrinol Metab; 2010 Jan; 95(1):43-51. PubMed ID: 19880787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of short-term maintenance treatment with cabergoline in microadenoma-related and idiopathic hyperprolactinemia.
    Buyukbayrak EE; Karageyim Karsidag AY; Kars B; Balcik O; Pirimoglu M; Unal O; Turan C
    Arch Gynecol Obstet; 2010 Nov; 282(5):561-6. PubMed ID: 20571820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical Remission after Cabergoline Withdrawal in Hyperprolactinemic Patients with Visible Remnant Pituitary Adenoma.
    Kim K; Park YW; Kim D; Ahn SS; Moon JH; Kim EH; Lee EJ; Ku CR
    J Clin Endocrinol Metab; 2021 Jan; 106(2):e615-e624. PubMed ID: 33079168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas.
    Sala E; Bellaviti Buttoni P; Malchiodi E; Verrua E; Carosi G; Profka E; Rodari G; Filopanti M; Ferrante E; Spada A; Mantovani G
    J Endocrinol Invest; 2016 Dec; 39(12):1377-1382. PubMed ID: 27245604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
    Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
    Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on the withdrawal of dopamine agonists in patients with hyperprolactinemia.
    Pereira AM
    Curr Opin Endocrinol Diabetes Obes; 2011 Aug; 18(4):264-8. PubMed ID: 21844709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
    Sabuncu T; Arikan E; Tasan E; Hatemi H
    Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SHORT-TERM DECLINE IN PROLACTIN CONCENTRATIONS CAN PREDICT FUTURE PROLACTIN NORMALIZATION, TUMOR SHRINKAGE, AND TIME TO REMISSION IN MEN WITH MACROPROLACTINOMAS.
    Tirosh A; Benbassat C; Shimon I
    Endocr Pract; 2015 Nov; 21(11):1240-7. PubMed ID: 26247115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels.
    Ciresi A; Amato MC; Guarnotta V; Lo Castro F; Giordano C
    Clin Endocrinol (Oxf); 2013 Dec; 79(6):845-52. PubMed ID: 23506485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of atherosclerosis after cessation of cabergoline therapy in patients with prolactinoma.
    Doğan BA; Arduç A; Tuna MM; Nasıroğlu NI; Işık S; Berker D; Güler S
    Anatol J Cardiol; 2016 Jun; 16(6):440-7. PubMed ID: 26680550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
    Colao A; Di Sarno A; Sarnacchiaro F; Ferone D; Di Renzo G; Merola B; Annunziato L; Lombardi G
    J Clin Endocrinol Metab; 1997 Mar; 82(3):876-83. PubMed ID: 9062500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy.
    Kharlip J; Salvatori R; Yenokyan G; Wand GS
    J Clin Endocrinol Metab; 2009 Jul; 94(7):2428-36. PubMed ID: 19336508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis.
    Colao A; Vitale G; Cappabianca P; Briganti F; Ciccarelli A; De Rosa M; Zarrilli S; Lombardi G
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1704-11. PubMed ID: 15070934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients.
    Vroonen L; Jaffrain-Rea ML; Petrossians P; Tamagno G; Chanson P; Vilar L; Borson-Chazot F; Naves LA; Brue T; Gatta B; Delemer B; Ciccarelli E; Beck-Peccoz P; Caron P; Daly AF; Beckers A
    Eur J Endocrinol; 2012 Nov; 167(5):651-62. PubMed ID: 22918301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cabergoline therapy for macroprolactinoma during pregnancy: a case report.
    Shahzad H; Sheikh A; Sheikh L
    BMC Res Notes; 2012 Oct; 5():606. PubMed ID: 23110890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.